About
Linagliptin is an oral antidiabetic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, used for the management of type 2 diabetes mellitus. It works by selectively inhibiting the enzyme DPP-4, which is responsible for the rapid degradation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving the active levels of these incretin hormones, linagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells.
This dual action helps to lower elevated blood glucose concentrations, particularly postprandial glucose, without increasing the risk of hypoglycemia when used as monotherapy. A notable advantage of linagliptin is its primary excretion via the enterohepatic system, meaning no dose adjustment is required for patients with any degree of renal impairment, including end-stage renal disease. It is typically used as an adjunct to diet and exercise, either alone or in combination with other antidiabetic agents.
Uses
- Treatment of type 2 diabetes mellitus.
- To improve glycemic control in adults.
- Used as monotherapy or in combination with other antidiabetic agents.
- As an adjunct to diet and exercise.
Directions For Use
Take this medication orally, once daily, with or without food, as directed by your healthcare provider. Swallow the tablet whole.
Benefits
- Effectively lowers blood glucose levels.
- Reduces HbA1c levels.
- Low risk of hypoglycemia (as monotherapy).
- Weight neutral effect.
- Can be used across a wide range of renal impairment without dose adjustment.
- Improves pancreatic beta-cell function.
Side Effects
- Nasopharyngitis
- Cough
- Headache
- Diarrhea
- Hypoglycemia (when combined with sulfonylureas/insulin)
- Pancreatitis (rare but serious)
- Joint pain (arthralgia)
- Skin reactions (e.g., rash, urticaria)
- Muscle pain
- Constipation
- Dizziness
- Upper respiratory tract infection
Safety Measures
- Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may increase the risk of hypoglycemia, especially if combined with other antidiabetic agents.
- Pregnancy - Not recommended during pregnancy. Insulin is generally preferred for glycemic control in pregnant women with diabetes. Consult a doctor.
- Breastfeeding - Avoid use during breastfeeding as it is unknown if linagliptin is excreted in human milk and could pose risks to the infant.
- Liver - Generally safe for use in patients with liver impairment, as it is primarily excreted unchanged via the enterohepatic system. No dose adjustment typically needed.
- Kidney - No dose adjustment is required for patients with any degree of renal impairment, including end-stage renal disease.
- Lung - No specific contraindications or major concerns related to lung conditions; however, general patient health should always be considered.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!